Search research articles
Contact Us
Filters
Showing results (1-10 of 138) with videos related to
Page
of 14
Sort By:
European Urology Oncology
|
June 29, 2026
Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe trial. Eur Urol Oncol 2026;9:404-12
Roberto Contieri, Rodolfo Hurle
The Journal of Urology
|
April 9, 2021
Editorial Comment
Rodolfo Hurle, Roberto Contieri, Massimo Lazzeri
World Journal of Urology
|
February 10, 2025
Comment to: "Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer"
Rodolfo Hurle, Roberto Contieri, Massimo Lazzeri
European Urology Focus
|
April 14, 2023
When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer
Roberto Contieri, Massimo Lazzeri, Rodolfo Hurle
European Urology Open Science
|
June 10, 2025
Re: Ben-Max de Ruiter, Jan E. Freund, C. Dilara Savci-Heijink, et al. Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor. Eur Urol Open Sci 2025;71:57-62
Roberto Contieri, Giovanni Lughezzani, Alessandro Uleri
European Urology Oncology
|
October 8, 2023
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596
Roberto Contieri, Patrick J Hensley, Ashish M Kamat
European Urology
|
March 21, 2026
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.008
Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 26, 2024
Comment to "Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer"
Roberto Contieri, Alessandro Uleri, Rodolfo Hurle, et al.
European Urology
|
February 4, 2025
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life
Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2026
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)
Roberto Contieri, Veronica Mollica, Shahrokh F Shariat, et al.
Page
of 14
Search research articles
Search
Showing results (1-10 of 138) with videos related to
Sort By:
Page
of 14
European Urology Oncology
|
June 29, 2026
Reply to Yue Chang's Letter to the Editor re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe trial. Eur Urol Oncol 2026;9:404-12
Roberto Contieri, Rodolfo Hurle
The Journal of Urology
|
April 9, 2021
Editorial Comment
Rodolfo Hurle, Roberto Contieri, Massimo Lazzeri
World Journal of Urology
|
February 10, 2025
Comment to: "Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer"
Rodolfo Hurle, Roberto Contieri, Massimo Lazzeri
European Urology Focus
|
April 14, 2023
When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer
Roberto Contieri, Massimo Lazzeri, Rodolfo Hurle
European Urology Open Science
|
June 10, 2025
Re: Ben-Max de Ruiter, Jan E. Freund, C. Dilara Savci-Heijink, et al. Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor. Eur Urol Open Sci 2025;71:57-62
Roberto Contieri, Giovanni Lughezzani, Alessandro Uleri
European Urology Oncology
|
October 8, 2023
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596
Roberto Contieri, Patrick J Hensley, Ashish M Kamat
European Urology
|
March 21, 2026
Re: Hiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.01.008
Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 26, 2024
Comment to "Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer"
Roberto Contieri, Alessandro Uleri, Rodolfo Hurle, et al.
European Urology
|
February 4, 2025
Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life
Rodolfo Hurle, Bruno Bernardini, Roberto Contieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 15, 2026
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)
Roberto Contieri, Veronica Mollica, Shahrokh F Shariat, et al.
Page
of 14